Jama OncologyPub Date : 2024-10-01DOI: 10.1001/jamaoncol.2024.3239
Giorgio Bogani, Francesco Raspagliesi
{"title":"Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification.","authors":"Giorgio Bogani, Francesco Raspagliesi","doi":"10.1001/jamaoncol.2024.3239","DOIUrl":"10.1001/jamaoncol.2024.3239","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1439-1440"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jama OncologyPub Date : 2024-10-01DOI: 10.1001/jamaoncol.2024.2637
Fiona Evans
{"title":"Cold Capping-A Medical Student's Perspective As a Caregiver.","authors":"Fiona Evans","doi":"10.1001/jamaoncol.2024.2637","DOIUrl":"10.1001/jamaoncol.2024.2637","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1315-1316"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jama OncologyPub Date : 2024-10-01DOI: 10.1001/jamaoncol.2024.3036
Qianwei Liu, Fen Yang, Krisztina D László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang
{"title":"Suicide Attempt and Suicide Death Among Spouses of Patients With Cancer.","authors":"Qianwei Liu, Fen Yang, Krisztina D László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang","doi":"10.1001/jamaoncol.2024.3036","DOIUrl":"10.1001/jamaoncol.2024.3036","url":null,"abstract":"<p><strong>Importance: </strong>Little is known about the risk of suicidal behavior in relation to having a spouse with a cancer diagnosis.</p><p><strong>Objective: </strong>To estimate the risk of suicide attempt and suicide death among spouses of patients with cancer.</p><p><strong>Design, setting, and participants: </strong>This nationwide cohort study in Denmark collected registry-based data from 1986 through 2016. Analyses were performed from August 8, 2022, to October 30, 2023. Individuals who had a spouse with a cancer diagnosed during 1986 to 2015 were compared with individuals whose spouse did not have a cancer diagnosis during the same period, randomly selected from the general population and matched by birth year and sex.</p><p><strong>Exposure: </strong>Having a spouse with a cancer diagnosis.</p><p><strong>Main outcomes and measures: </strong>Suicide attempt was identified through the Danish National Patient Register and the Danish Psychiatric Central Research Register, whereas suicide death was identified through the Danish Causes of Death Register, through 2016. Flexible parametric and Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for suicide attempt and suicide death among spouses of patients with a cancer diagnosis.</p><p><strong>Results: </strong>The study included 409 338 exposed individuals and 2 046 682 unexposed individuals (median [IQR] age at cohort entry for both groups, 63 [54-70] years; 55.4% women). During the follow-up, 2714 incident cases of suicide attempt among exposed individuals (incidence rate [IR], 62.6 per 100 000 person-years) and 9994 among unexposed individuals (IR, 50.5 per 100 000 person-years) were identified, as well as 711 cases of suicide death among the exposed individuals (IR, 16.3 per 100 000 person-years) and 2270 among the unexposed individuals (IR, 11.4 per 100 000 person-years). An increased risk of suicide attempt (HR, 1.28; 95% CI, 1.23-1.34) and suicide death (HR, 1.47; 95% CI, 1.35-1.60) was observed among spouses of patients with cancer throughout the follow-up. The increased risk was particularly notable during the first year after the cancer diagnosis, with an HR of 1.45 (95% CI, 1.27-1.66) for suicide attempt and 2.56 (95% CI, 2.03-3.22) for suicide death. There was a greater risk increase for both suicide attempt and suicide death when the cancer was diagnosed at an advanced stage or when the spouse died after the cancer diagnosis.</p><p><strong>Conclusions and relevance: </strong>These findings suggest a need for clinical and societal awareness to prevent suicidal behaviors among spouses of patients with cancer, particularly during the first year following the cancer diagnosis.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1323-1330"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.","authors":"Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann","doi":"10.1001/jamaoncol.2024.3065","DOIUrl":"10.1001/jamaoncol.2024.3065","url":null,"abstract":"<p><strong>Importance: </strong>Immune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur.</p><p><strong>Objective: </strong>To determine the incidence of CVAEs and analyze data on the management of myocarditis in patients exposed to ICIs.</p><p><strong>Data sources: </strong>PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception were searched on April 4, 2023.</p><p><strong>Study selection: </strong>Two separate studies were performed. Key inclusion criteria for study 1 were phases 1 to 4 trials involving adults with malignant neoplasms treated with an ICI and toxicity data; for study 2, publications (case reports and retrospective analyses) on clinical manifestations and treatment of patients with ICI-induced CVAEs. Studies with dose escalation or fewer than 11 patients in each group and all case reports, retrospective analyses, letters, reviews, and editorials were excluded from study 1. Studies not published in English were excluded from study 2.</p><p><strong>Data extraction and synthesis: </strong>The PRISMA guidelines and Cochrane Handbook for Systematic Reviews were followed. Data were extracted independently by 2 researchers. A meta-analysis of the incidence of CVAEs in clinical trials and a systematic review of the evidence for the management of myocarditis were performed. Data were pooled using a random-effects model.</p><p><strong>Main outcomes and measures: </strong>In study 1, the primary outcome was incidence CVAEs in clinical trials with ICIs and ICI combination therapies. Study 2 examined evidence supporting specific management strategies that may decrease the mortality rate of myocarditis. The primary outcomes were planned before data collection began.</p><p><strong>Results: </strong>In study 1, a total of 83 315 unique participants in 589 unique trials were included in the meta-analysis. Incidence of CVAEs induced by anti-programmed cell death 1 and/or programmed cell death ligand 1 was 0.80% (95% CI, 0%-1.66%) in clinical trials, with no differences between the compounds, except for cemiplimab, which was associated with a higher risk of CVAEs. Incidence of CVAEs following ipilimumab treatment was 1.07% (95% CI, 0%-2.58%). The incidence of myocarditis was significantly higher following treatment with dual ICIs. However, CVAE incidence was not higher with dual ICIs, ICI combination with chemotherapy, or tyrosine kinase inhibitors. Evidence from randomized clinical trials on recommended monitoring and treatment strategies for ICI-induced myocarditis was lacking. Study 2 showed that myocarditis-associated mortality occurred in 83 of 220 patients (37.7%). Prospective data from 40 patients with myocarditis indicated that systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and the addition of ruxolitinib, may decrease the mortalit","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1390-1399"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jama OncologyPub Date : 2024-10-01DOI: 10.1001/jamaoncol.2024.2503
Daniel R Sikavi, Kai Wang, Wenjie Ma, David A Drew, Shuji Ogino, Edward L Giovannucci, Yin Cao, Mingyang Song, Long H Nguyen, Andrew T Chan
{"title":"Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk.","authors":"Daniel R Sikavi, Kai Wang, Wenjie Ma, David A Drew, Shuji Ogino, Edward L Giovannucci, Yin Cao, Mingyang Song, Long H Nguyen, Andrew T Chan","doi":"10.1001/jamaoncol.2024.2503","DOIUrl":"10.1001/jamaoncol.2024.2503","url":null,"abstract":"<p><strong>Importance: </strong>Aspirin reduces the risk of colorectal cancer (CRC). Identifying individuals more likely to benefit from regular aspirin use for CRC prevention is a high priority.</p><p><strong>Objective: </strong>To assess whether aspirin use is associated with the risk of CRC across different lifestyle risk factors.</p><p><strong>Design, setting, and participants: </strong>A prospective cohort study among women in the Nurses' Health Study (1980-2018) and men in the Health Professionals Follow-Up Study (1986-2018) was conducted. Data analysis was performed from October 1, 2021, to May 22, 2023.</p><p><strong>Exposures: </strong>A healthy lifestyle score was calculated based on body mass index, alcohol intake, physical activity, diet, and smoking with scores ranging from 0 to 5 (higher values corresponding to a healthier lifestyle). Regular aspirin use was defined as 2 or more standard tablets (325 mg) per week.</p><p><strong>Main outcome and measures: </strong>Outcomes included multivariable-adjusted 10-year cumulative incidence of CRC, absolute risk reduction (ARR), and number needed to treat associated with regular aspirin use by lifestyle score and multivariable-adjusted hazard ratios for incident CRC across lifestyle scores.</p><p><strong>Results: </strong>The mean (SD) baseline age of the 107 655 study participants (63 957 women from the Nurses' Health Study and 43 698 men from the Health Professionals Follow-Up Study) was 49.4 (9.0) years. During 3 038 215 person-years of follow-up, 2544 incident cases of CRC were documented. The 10-year cumulative CRC incidence was 1.98% (95% CI, 1.44%-2.51%) among participants who regularly used aspirin compared with 2.95% (95% CI, 2.31%-3.58%) among those who did not use aspirin, corresponding to an ARR of 0.97%. The ARR associated with aspirin use was greatest among those with the unhealthiest lifestyle scores and progressively decreased with healthier lifestyle scores (P < .001 for additive interaction). The 10-year ARR for lifestyle scores 0 to 1 (unhealthiest) was 1.28%. In contrast, the 10-year ARR for lifestyle scores 4 to 5 (healthiest) was 0.11%. The 10-year number needed to treat with aspirin was 78 for participants with lifestyle scores 0 to 1, 164 for score 2, 154 for score 3, and 909 for scores 4 to 5. Among the components of the healthy lifestyle score, the greatest differences in ARR associated with aspirin use were observed for body mass index and smoking.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, aspirin use was associated with a greater absolute reduction in risk of CRC among individuals with less healthy lifestyles. The findings of the study suggest that lifestyle risk factors may be useful to identify individuals who may have a more favorable risk-benefit profile for cancer prevention with aspirin.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1354-1361"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}